The Medicines Company (MDCO)
-NasdaqGS 32.53 
1.18(3.50%) 23 May 04:00 SGT|After Hours
:
32.53 0.00 (0.00%) 23 May 04:31 SGT
| Prev Close: | 33.71 |
|---|
| Open: | 33.40 |
|---|
| Bid: | 31.01 x 1000 |
|---|
| Ask: | 37.46 x 800 |
|---|
| 1y Target Est: | 37.14 |
|---|
| Beta: | 0.93 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 30.85 - 34.33 |
|---|
| 52wk Range: | 20.04 - 37.40 |
|---|
| Volume: | 3,550,393 |
|---|
| Avg Vol (3m): | 879,070 |
|---|
| Market Cap: | 1.76B |
|---|
| P/E (ttm): | 55.32 |
|---|
| EPS (ttm): | 0.59 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Stocks Stage Broad Advance; Bristol-Myers Leads Medicalsat Investor's Business Daily(Thu, 00:09 SGT)
- Stocks Get A Boost From Dovish Fed Remarksat Investor's Business Daily(Wed, 22 May)
- MEDICINES CO /DE Files SEC form 8-K, Other EventsEDGAR Online(Mon, 20 May)
- IBD 50: Top 5 Medical Stocks Include Celgene, Actavisat Investor's Business Daily(Sat, 18 May)
- MEDICINES CO /DE FinancialsEDGAR Online Financials(Sat, 18 May)
- A Disconnect Between Future Prospects of Drug Candidates Versus Where Share Price is Currently Trading: Portfolio Manager Finny Kuruvilla Discusses the Biotech and Pharmaceutical SectorsWall Street Transcript(Fri, 17 May)
- Why The Medicines Company May Be About to Take Offat Motley Fool(Thu, 16 May)
- The Medicines Company CEO Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript)at Seeking Alpha(Thu, 16 May)
- Pediatric Approval for MDCO/BMY's RecothromZacks(Thu, 16 May)
- Alnylam takes smaller 1Q loss on lower costsAP(Tue, 7 May)
Key Statistics
| Forward P/E (1 yr): | 21.12 |
|---|
| P/S (ttm): | 3.10 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.98 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.32 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 0.91 |
|---|
Business Summary
The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients ...
View More